Articles by Nicolas Girard, MD, PhD
The phase 2 trial evaluated subcutaneous amivantamab and lazertinib as a first-line therapy for EGFR-mutated NSCLC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.